Literature DB >> 22298637

Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study.

Masanobu Miura1, Nobuyuki Shiba, Kotaro Nochioka, Tsuyoshi Takada, Jun Takahashi, Haruka Kohno, Hiroaki Shimokawa.   

Abstract

AIMS: Heart failure with preserved ejection fraction (HFpEF) is characterized by multiple co-morbidities, including chronic kidney disease that is one of the prognostic risks for these patients. This study was performed to evaluate the value of determination of albuminuria using a urine dipstick test (UDT), combined with estimated glomerular filtration rate (eGFR), for predicition of mortality in HFpEF. METHODS AND
RESULTS: We enrolled 2465 consecutive patients with overt HF with EF ≥50% in our Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) study (NCT00418041). We defined trace or more UDT as positive. We divided the patients into the following four groups based on eGFR and UDT; group 1 (G1) (eGFR ≥60, negative UDT), G2 (eGFR ≥60, positive UDT), G3 (eGFR <60, negative UDT), and G4 (eGFR <60, positive UDT). In total, 29.5% of the HFpEF patients had a positive UDT. HFpEF patients with a positive UDT were characterized by higher brain natriuretic peptide levels and frequent histories of hypertension or diabetes. During a mean follow-up of 2.5 years, HFpEF patients with a positive UDT showed higher mortality in each stratum of eGFR levels. A multivariable adjusted Cox model showed that when compared with G1 (reference), the hazard ratio of all-cause death for G2, G3, and G4 was 2.44 (95% confidence interval 1.47-4.05, P=0.001), 1.43 (0.92-2.23, P=0.12), and 2.71 (1.72-4.27, P<0.001), respectively. Furthermore, the prognostic value of a positive UDT was robust for both cardiovascular and non-cardiovascular deaths.
CONCLUSIONS: These results indicate that measurement of albuminuria in addition to eGFR is useful for appropriate risk stratification in HFpEF patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298637     DOI: 10.1093/eurjhf/hfs001

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  12 in total

1.  Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Eileen O'Meara; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; James C Fang; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2018-11       Impact factor: 8.790

Review 2.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

3.  Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.

Authors:  Mauro Gori; Michele Senni; Deepak K Gupta; David M Charytan; Elisabeth Kraigher-Krainer; Burkert Pieske; Brian Claggett; Amil M Shah; Angela B S Santos; Michael R Zile; Adriaan A Voors; John J V McMurray; Milton Packer; Toni Bransford; Martin Lefkowitz; Scott D Solomon
Journal:  Eur Heart J       Date:  2014-06-30       Impact factor: 29.983

4.  Renal function on admission modifies prognostic impact of diuretics in acute heart failure: a propensity score matched and interaction analysis.

Authors:  Yuya Matsue; Atsushi Shiraishi; Nobuyuki Kagiyama; Kazuki Yoshida; Teruyoshi Kume; Hiroyuki Okura; Makoto Suzuki; Akihiko Matsumura; Kiyoshi Yoshida; Yuji Hashimoto
Journal:  Heart Vessels       Date:  2016-02-18       Impact factor: 2.037

5.  Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction.

Authors:  Daniel H Katz; Jacob A Burns; Frank G Aguilar; Lauren Beussink; Sanjiv J Shah
Journal:  JACC Heart Fail       Date:  2014-10-01       Impact factor: 12.035

6.  Albuminuria and Dipstick Proteinuria for Predicting Mortality in Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Wei Liang; Qian Liu; Qiong-Ying Wang; Heng Yu; Jing Yu
Journal:  Front Cardiovasc Med       Date:  2021-05-13

7.  Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.

Authors:  Yasuhiko Sakata; Nobuyuki Shiba; Jun Takahashi; Satoshi Miyata; Kotaro Nochioka; Masanobu Miura; Tsuyoshi Takada; Chiharu Saga; Tsuyoshi Shinozaki; Masafumi Sugi; Makoto Nakagawa; Nobuyo Sekiguchi; Tatsuya Komaru; Atsushi Kato; Mitsumasa Fukuchi; Eiji Nozaki; Tetsuya Hiramoto; Kanichi Inoue; Toshikazu Goto; Masatoshi Ohe; Kenji Tamaki; Setsuro Ibayashi; Nobumasa Ishide; Yukio Maruyama; Ichiro Tsuji; Hiroaki Shimokawa
Journal:  Eur Heart J       Date:  2015-01-30       Impact factor: 29.983

8.  Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial.

Authors:  Kotaro Nochioka; Yasuhiko Sakata; Masanobu Miura; Takashi Shiroto; Jun Takahashi; Chie Saga; Yasuko Ikeno; Nobuyuki Shiba; Tsuyoshi Shinozaki; Masafumi Sugi; Makoto Nakagawa; Tatsuya Komaru; Atsushi Kato; Eiji Nozaki; Kaoru Iwabuchi; Tetsuya Hiramoto; Kanichi Inoue; Masatoshi Ohe; Kenji Tamaki; Ichiro Tsuji; Hiroaki Shimokawa
Journal:  ESC Heart Fail       Date:  2019-10-24

9.  Cardiorenal biomarkers in acute heart failure.

Authors:  Rajiv Choudhary; Dipika Gopal; Ben A Kipper; Alejandro De La Parra Landa; Hermineh Aramin; Elizabeth Lee; Saloni Shah; Alan S Maisel
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

10.  Clinical characteristics and prognostic factors in elderly patients with chronic heart failure -A report from the CHART-2 study.

Authors:  Masayuki Sato; Yasuhiko Sakata; Kenjiro Sato; Kotaro Nochioka; Masanobu Miura; Ruri Abe; Takuya Oikawa; Shintaro Kasahara; Hajime Aoyanagi; Shinsuke Yamanaka; Takahide Fujihashi; Hideka Hayashi; Takashi Shiroto; Koichiro Sugimura; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal:  Int J Cardiol Heart Vasc       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.